Qishiwei Zhenzhu Pills Protect Against Cerebral Ischemia via the P53 /Cytochrome C/Apoptotic Protease Activating Factor 1‐Mediated Mitochondrial Apoptosis Pathway
CNS Neuroscience & Therapeutics · 2025
DOI: 10.1111/cns.70476 ↗Kurz gefasst
Fachartikel in der Zeitschrift CNS Neuroscience & Therapeutics, 2025. Verfasst von Yinglian Song und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China. Hauptthemen laut MEDLINE: Apoptosis, Mitochondria, Drugs, Chinese Herbal, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Sichuan Province, Chengdu University of Traditional Chinese Medicine, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Background
Qishiwei Zhenzhu pills (QSWZZP, Tibetan name: ) originated from Ershiwuwei Zhenzhu mother pills in the eighth century AD and are currently included in the Chinese Pharmacopoeia (2020). QSWZZP calm the mind, activate the medians, regulate qi, and harmonize the blood. QSWZZP have significant therapeutic effects in cerebral ischemia. However, QSWZZP's complex and diverse multi‐herb chemical composition has presented challenges in identifying their active ingredients, which have hitherto remained unclarified. Therefore, the present study focusses on the identification of QSWZZP's active ingredients and their therapeutic mechanisms.
Aims
To analyze the distribution of QSWZZP's components in the blood and tissues for the treatment of cerebral ischemia, to identify the biomarkers after drug intervention, and to explore the mechanism of action of QSWZZP in terms of the mitochondrial apoptosis pathway.
Methods
Ultra‐high performance liquid chromatography with quadrupole time‐of‐flight mass spectrometry was used for qualitative and metabolomic analysis of the distribution of QSWZZP's components in the blood and tissues. A middle cerebral artery occlusion (MCAO) rat model was used to evaluate and measure neurobehavioral changes, the ratio of cerebral infarction, the rate of apoptosis‐positive cells in the brain tissue, and the pathological changes in the cerebral cortex, hippocampus, and diencephalon. mRNA, protein, and fluorescence expressions of apoptosis‐inducing factor (AIF), P53, cytochrome C (Cyt C), apoptotic protease activating factor‐1 (APAF‐1), cleaved caspase‐8, B‐cell lymphoma‐extra‐large, and N‐myc downstream‐regulated gene family member 4 (NDRG4) were determined in the rat brain tissues via real‐time polymerase chain reaction, western blotting, and immunofluorescence. In addition, molecular docking was used to screen the active components of QSWZZP against mitochondria‐mediated apoptosis.
Results
Thirty‐three new compounds were identified, including 13 triterpenoids and nine flavonoids. Among them, 15 blood‐entry, 21 urine‐entry, three brain‐entry, seven liver‐entry, and four kidney‐entry components were identified. QSWZZP significantly improved neurobehavioral abnormalities and reduced the cerebral infarction rate in the MCAO rats by significantly decreasing AIF, P53, Cyt C, APAF‐1, and cleaved caspase‐8 mRNA expressions and Cyt C and APAF‐1 protein expressions, as well as increasing NDRG4 protein expression in the rat brain tissues. Molecular docking revealed that the active ingredients of QSWZZP against mitochondrial‐mediated apoptosis were arjunic acid, cholic acid, and phyllaemblic acid.
Conclusion
In this study, 45 components of QSWZZP were qualitatively analyzed, and the metabolic pathways of the related products were clarified. The potential treatment mechanism of QSWZZP may be related to the modulation of the folate biosynthesis metabolic and P53/Cyt C/APAF‐1‐mediated mitochondrial apoptosis pathways. This study may serve as the foundation for subsequent pharmacokinetic experiments and analysis of the material basis of the drug effect of QSWZZP in cerebral ischemia treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
- College of Ethnomedicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
ORCID-Profile: Zhang Wang
Förderung
- Natural Science Foundation of Sichuan Province
- Chengdu University of Traditional Chinese Medicine
- China Postdoctoral Science Foundation
Zitieren
APA
Song, Y., Song, G., Lizhen, L., Liang, Y., Han, M., Yang, Y., Feng, Q., Li, Y., Zhang, J., Xu, M., Zeweng, Y., Jiang, M., & Wang, Z. (2025). Qishiwei Zhenzhu Pills Protect Against Cerebral Ischemia via the P53 /Cytochrome C/Apoptotic Protease Activating Factor 1‐Mediated Mitochondrial Apoptosis Pathway. CNS Neuroscience & Therapeutics. https://doi.org/10.1111/cns.70476
Vancouver
Song Y, Song G, Lizhen L, Liang Y, Han M, Yang Y, et al. Qishiwei Zhenzhu Pills Protect Against Cerebral Ischemia via the P53 /Cytochrome C/Apoptotic Protease Activating Factor 1‐Mediated Mitochondrial Apoptosis Pathway. CNS Neuroscience & Therapeutics. 2025. doi:10.1111/cns.70476
BibTeX
@article{Song2025,
author = {Song, Yinglian and Song, Guili and Lizhen, Lame and Liang, Yan and Han, Mengtian and Yang, Yichu and Feng, Qiaoqiao and Li, Yi and Zhang, Jingwen and Xu, Min and Zeweng, Yongzhong and Jiang, Miao and Wang, Zhang},
title = {Qishiwei Zhenzhu Pills Protect Against Cerebral Ischemia via the P53 /Cytochrome C/Apoptotic Protease Activating Factor 1‐Mediated Mitochondrial Apoptosis Pathway},
journal = {CNS Neuroscience & Therapeutics},
year = {2025},
doi = {10.1111/cns.70476}
}
EUVIMED